We bring clarity to cell therapy development and manufacturing.
Providing the focus, platforms, and expertise needed to make delivery of immune-oncology and regenerative medicine cell therapies mainstream.
CDMO services, platforms, and technologies built to excel.
Complex scientific, operational, and economic questions emerge at every stage in cell therapy development and manufacturing. Cellistic was purpose-built to answer those questions, empowering your team to move forward with clarity and conviction.
We can take your innovation from idea to edited and banked iPSC-based cell line, and then from cell line to drug product. At each step forward, your program is the hands of a single, experienced development and manufacturing team specifically assembled to unlock the full potential of your cell therapy.
The global leader in allogeneic iPSC-derived cell therapy manufacturing.
15+
Years’ experience in advancing iPSC science
32,000
Square feet of GMP manufacturing space
100L
Scale we achieve in stirred-tank bioreactors
42%
Percentage of team with PhDs
400+
GMP Batches Released
9 | 5 | 6
GMP cleanrooms, cell line development suites and PD labs
Let’s not make the world wait any longer for your cell therapy.
We’re the “Making Your Cell Therapies Mainstream” CDMO. And your access to our path-clearing team and capabilities is just a call or email away.
Where the science and business of cell therapy meet.
These are just a handful of the key milestones that have marked our evolution into a global leader in cell therapy manufacturing.
Ncardia, our sister company, continues to lead the way in pioneering how iPSCs are leveraged for drug discovery.
And we never stop giving immune oncology and regenerative medicine cell therapy developers new opportunities to scale to commercial viability clearly and confidently.
2026
Echo™-Endothelial, Echo™-Cardio and Echo™-T ready
2025
Echo™-NK platform ready
2024
Certification of our GMP manufacturing facility
2023
Establishment of GMP facility
2021-2023
Development of iPSC-based immune cell manufacturing platforms (Pulse™ and Echo™)
2022
Launch of Cellistic, Ncardia’s allogeneic cell therapy manufacturing brand
2021
$60 million investment as part of a strategic partnership with Kiniciti
2020
First iPSC-based cell therapy partnership: BlueRock Therapeutics
2019
Launch of Ncardia’s large- scale iPSC manufacturing platform
2016
First iPSC-based drug discovery screening activities performed
2011
Formulation of Pluriomics /Ncardia, an iPSC-derived research product company
Meet the people and the place that bring your cell therapy to life.
Get to know the team that leads Cellistic, where we produce mainstream cell therapies, and how you can be a part of our success.
Every cell therapy development story begins with a vision: “We believed in the power of cell therapy to . . . ”. How do you want to change the world? How will you get there? That’s the chapter we’d like to help you write. Let’s start now.
News
